Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Who toots their own horn? And on something that hasn't happened yet?
1 Thing: Please don't buy any more.
Oooh noooo! The sky is falling, Chicken Little!
Meh. Real investors don't sweat these trading bands.
But you most certainly did say so: "Pretty sure what we say and/or share on iHub and Twitter doesn't impact stock at all."
And what did GameStop go viral based on? Acquisition? Amazing overperformance? No. No major fundamental event analogous to an FDA device play.
The SP has gone up 20% in the last 2 weeks in part by long investors getting the word out to social media influencers in the financial space. Still 100% certain?
Appreciate your holding and 2 years. But try 6 years and more for true longs.
We know what we own and don't bellyache at every company update. As the saying goes: if you can't handle the heat, get out of the kitchen.
If you can't celebrate your own holdings even when there isn't good news, then you don't know what you truly own.
And if your selective memory chooses to not recall all the progress made in the last 2 years, you should step into the light: Patents, additional testing, continued partnership and training with Mayo, BDD designation, final action items for IDE submittal. Yeah, sounds like much ado about nothing the last 2 years.
Seen this MMQB pattern for the last 2 years too.
He's not making that point to replace IDE submission news.
Let's not forget your historical pattern of being a fair weather shareholder.
Conviction matters.
What is shared on Twitter/X doesn't impact a stock? Are you sure?
Maybe you're not a digital native, but social media channels are as effective (if not more in certain cases) as a traditional PR release. Ever here of GameStop or meme stocks?
What happens on social media can almost certainly drive awareness and by direct correlation research and volume.
Nope.
Don't fret.
By tomorrow, he'll be Debbie Downer again.
Based on your optimism, my IDE projection is July 2034.
Progress progress progress
He's pinned himself into the corner now with all his doublespeak about RDGL and MK.
And you know how animals who are pinned into a corner behave.
Integrity not the top skill in a for-profit CEO.
- Fortune 500 CEOs of present and past fail tremendously at that. Jack Welch. Jaime Dimon. On and on.
Progress. That's what a critical skill you need from a CEO.
- MK showing it in spades.
There you go: no legal obligation.
I make wrong forecasts too. I move on. Life doesn't end.
Sorry you're still bent out of shape of a "forecast" that has no official impact.
Sorry that you live life through hazy filters.
We read it.
It means:
- Real progress this entire time he's been "radio silent" with you (You were wrong)
- There's been interactions between MK and FDA (You were wrong)
- Still progressing and ever closer to IDE submission (You were wrong)
You should speak.
Easily swayed by the fake news and speculations.
This guy sways like a grass in the winds.
Most days it's gloomy and dark because of the fake news.
One whiff of actual good, real news: oh my I'm high as a kite!
SMH
Not a downdate; a date; and another sign of progress.
Vivos/RDGL/MK did not submit the Genotoxicity Chemical Characterization Protocol "late"; from the horse's (MK's) mouth: "Per the FDA recommendation, the proposed Genotoxicity Chemical Characterization Protocol was sent to the FDA for their comments on 7/23/23"
"Unfortunately, it has taken this long to get on their schedule."
Your "facts" are misrepresentations of the actual facts.
Why does MK need to withdraw his forecast? Is he obligated to by the SEC?
Are you losing sleep over it? Rhetorical question.
What facts?
End the end of the day, I believe all your arguments boil down to this:
- MK is taking too slow
The objective reality is not a simple binary yes/no.
Factors abound for the slower progression; and not all of them center on MK.
So the eternal question remains: Why harp on this ad nauseum?
Either you wait patiently or you just sell.
Thanks CH!
How does anyone HERE know with certainty that they haven't been in talks with the FDA in the last couple months?
If they have an open line of communication that doesn't require face-to-face meetings, then there might be ongoing dialogue.
We'll learn more in the coming weeks.
But to opine that MK isn't proactively engaging with the FDA currently is just pure speculation.
20 years - The tech still matters.
7 years - MK has saved the company and positioning for IDE submittal.
2 years - Alleged no activity (by one poster); yet here we are in the EFS pathway to submit IDE in the final stretch.
- An OTC on a tight budget has not moved as quickly as some prefer --> doesn't negate actual progress
- Partnered with Mayo Clinic (world class hospital) for years and with increasing collaboration over time --> company and tech are clearly relevant
Great recap.
MK did a phenomenal job right out of the gates to bring Vivos to better financial footing that gave current and potential investors much needed confidence moving forward.
He's not perfect, but he's been pretty solid.
Has he made some mistakes? Probably.
Anything detrimental? Doesn't seem like yet.
If that logic is applied that the past doesn't matter today...
Then your complaints about MK on the last two years also are irrelevant.
Following that logic, only the present matters.
So why are you constantly beating a dead horse from two years ago???
Doesn't matter how long ago it was: It was landmark for the company to get through such a crazy mess.
Mayo Clinic involvement was and is still greatly relevant even before human trials.
Example: If I'm an EV charging component vendor and Tesla becomes a strategic partner as I'm on path to go live with my product, Tesla's inclusion makes a huge and lasting splash on my current investors (to hold tight; maybe invest more) and for prospective investors to consider investment.
Mayo still has significant current impact here.
Major reason to believe in RDGL in an OTC minefield of scams.
Let's stay on topic: You applied ad hominen yesterday. You apologized. We're done.
Let's stay on RDGL rest of the way.
Yes, where was the relevance by your attack to RDGL?
Yet MK's success at cleaning up the previous toxic financial mess can never be glossed over or understated.
And his pièce de résistance was getting Mayo Clinic on board as a strategic partner.
You rile on his past "issues".
Same logic applies to applaud his past successes.
Can't have it one way only.
Well the facts are you yourself applied an ad hominem attack to another board poster.
I believe MK has some sense of urgency.
Forecast range for IDE submission: Q4 '23 - end of Q2 '24 (may surprise with this Sep; but feeling low probability).
Again, the risk/reward/dilution IDE formula has a higher percentage when you lean towards accuracy vs speed vs dilution.
IsoPet is not the main problem.
I don't think it's the main leak in the budget. Maybe I'm wrong.
The main challenge today is getting the IDE submission packaged right.
Even the timing of the IDE is secondary to packaging the IDE air tight.
Methinks we have the motive: jilted former employee with shares in hand taking out his vengeance with vitriol with no end in sight.
I never (mis)understood Mayo Clinic's role as to help facilitate IDE submission.
They're here to mainly be involved with human trials when we get to that stage.
IDK, maybe they help with some consultation or prep before human trials but wasn't expecting major contributions in the IDE effort.
"sure seems to confirm MK has nothing of substance to say and remains mired in the hopeless IsoPet business at expense of saving RDGL"
Yes, that's your opinion and interpretation.
Not mine. I believe he's working both swim lanes because he sees the long game and isn't stressed about funding and imaginary deadlines posed by retail investors.
Because he let you go? Hmm...
Ah...I think you're on to something here!
See nothing wrong about being focused on both.
IsoPet got us here.
Company focus on both can be objectively interpreted as MK isn't stressed about funding at the moment (has the long view of two future main revenue streams) AND that IDE submission may not be too far off. The exact timeline will always be up for debate.
Tell us something new on the SP. This is old news.
You paint the two possible broad scenarios from here on out. Agree with the POV.
Others will only spell a doomsday prophecy of imminent bankruptcy--highly unlikely and only meant as fear porn.